Phase 1/2a Study of the Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Azacitidine and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine Alone for the Treatment of Patients With Relapsed and Refractory Peripheral T-Cell Lymphoma

Trial Profile

Phase 1/2a Study of the Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Azacitidine and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine Alone for the Treatment of Patients With Relapsed and Refractory Peripheral T-Cell Lymphoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Azacitidine (Primary) ; Durvalumab (Primary) ; Pralatrexate (Primary) ; Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2017 Planned initiation date changed from 15 Sep 2017 to 1 Oct 2017.
    • 31 Jul 2017 Planned number of patients changed from 45 to 148.
    • 31 Jul 2017 Planned initiation date changed from 15 Jun 2017 to 15 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top